What is ENDRA Life Sciences?
Founded in 2009 and headquartered in Ann Arbor, Michigan, ENDRA Life Sciences operates at the intersection of medical technology and diagnostic innovation. The company specializes in the development of non-invasive imaging solutions designed to improve the early detection and monitoring of liver disease. By leveraging sophisticated acoustic and light-based technologies, ENDRA aims to provide clinicians with actionable insights that were previously accessible only through invasive procedures. As the firm transitions into a more mature enterprise-level entity, its focus remains on clinical validation and the commercialization of its core diagnostic platforms, positioning itself as a critical player in the global hepatology market.
How much funding has ENDRA Life Sciences raised?
ENDRA Life Sciences has raised a total of $27.9M across 4 funding rounds:
Stock Offering
$8.4M
Debt
$150K
Private Equity
$4.9M
Private Equity
$14.4M
Stock Issuance/Offering (2017): $8.4M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Private Equity (2025): $4.9M, investors not publicly disclosed
Private Equity (2025): $14.4M, investors not publicly disclosed
Key Investors in ENDRA Life Sciences
PPP
Public-Private Partnership
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for ENDRA Life Sciences?
With the recent infusion of capital, ENDRA Life Sciences is well-positioned to accelerate its clinical development programs and expand its commercial footprint. The strategic allocation of these funds will likely prioritize the scaling of manufacturing capabilities and the expansion of regulatory approval efforts across key international markets. As the company moves beyond its initial development phase, the focus will shift toward achieving widespread clinical adoption and establishing long-term partnerships with healthcare providers. This growth trajectory suggests a deliberate move toward market leadership, supported by a robust balance sheet and a clear mandate to address the growing global burden of chronic liver conditions through technological innovation.
See full ENDRA Life Sciences company page
